Quest Diagnostics Incorporated (DGX)

Currency in USD
176.47
+2.20(+1.26%)
Real-time Data·

DGX Earnings

Latest Release
Jul 22, 2025
EPS / Forecast
2.62 / 2.57
Revenue / Forecast
2.76B / 2.73B
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
09/2025--/2.51--/2.73B----Free Sign Up
06/20252.62/2.572.76B/2.73B+1.95%+1.1%Free Sign Up
03/20251.94/2.162.65B/2.64B-10.19%+0.38%Free Sign Up
12/20242.23/2.192.62B/2.58B+1.83%+1.55%Free Sign Up
09/20242.3/2.262.49B/2.43B+1.77%+2.47%Free Sign Up
06/20242.35/2.332.4B/2.39B+0.86%+0.42%Free Sign Up
03/20242.04/1.862.37B/2.29B+9.68%+3.49%Free Sign Up
12/20232.15/2.112.29B/2.25B+1.9%+1.78%Free Sign Up
09/20232.22/2.192.3B/2.27B+1.37%+1.32%Free Sign Up
06/20232.3/2.282.34B/2.25B+0.88%+4%Free Sign Up

All numbers in USD

Quest Diagnostics Incorporated Earnings Call Summary for Q2/2025

  • Quest Diagnostics reported Q2 2025 adjusted EPS of $2.62, beating estimates of $2.57, with revenue of $2.76 billion exceeding forecast of $2.73 billion
  • Consolidated revenues increased 15.2% year-over-year, with organic revenue growth at 5.2%; stock rose 3.33% in pre-market trading to $172 per share
  • Full-year 2025 revenue guidance set at $10.8-$10.92 billion, with adjusted EPS expected between $9.63-$9.83 and organic revenue growth of 3.5-4%
  • Company highlighted new product launches in diagnostics and automation improvements; plans to continue investing in Project Nova and modernization efforts
  • Executives addressed potential healthcare policy changes and tariff impacts, noting existing contracts and legislative efforts for PAMA reform as mitigating factors
Last Updated: 22/07/2025, 14:32
Read Full Transcript

FAQ

What Is Quest Diagnostics's Earnings Per Share (TTM)?

The Quest Diagnostics EPS (TTM) is 8.48.

When Is The Next Quest Diagnostics Earnings Date?

Quest Diagnostics will release its next earnings report on 27 Oct 2025.

What Is Quest Diagnostics’s Revenue Forecasts For Upcoming Quarters?

Quest Diagnostics’s revenue forecast is 2.73B.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.